Ledaga
Chlormethine Gel for Cutaneous T-Cell Lymphoma (Mycosis Fungoides)
Quick Facts About Ledaga
Key Takeaways About Ledaga
- Targeted topical cancer therapy: Ledaga delivers chlormethine directly to affected skin areas in mycosis fungoides, minimising systemic absorption and whole-body side effects
- Strict eye safety: The gel must never contact the eyes, nose, mouth, or lips – accidental eye exposure can cause severe permanent damage including blindness
- Caregiver protection required: Anyone applying the gel to a patient must wear disposable nitrile gloves and avoid direct skin contact with the medication
- Refrigerated storage essential: Store at 2–8°C and discard after 60 days, whether opened or unopened – apply within 30 minutes of removal from the fridge
- Skin reactions are common: Dermatitis, skin infections, and itching frequently occur at the application site – your doctor may pause treatment to manage these reactions
What Is Ledaga and What Is It Used For?
Ledaga is a topical gel containing chlormethine (mechlorethamine), an alkylating anticancer agent. It is specifically used to treat cutaneous T-cell lymphoma (CTCL) of the mycosis fungoides (MF) type in adult patients, providing targeted skin-directed therapy against malignant T-lymphocytes.
Cutaneous T-cell lymphoma (CTCL) is a group of rare non-Hodgkin lymphomas characterised by the malignant proliferation of T-lymphocytes that primarily affects the skin. Mycosis fungoides (MF) is the most common subtype, accounting for approximately 50% of all CTCL cases. In MF, certain T-cells of the immune system become cancerous and migrate to the skin, where they cause characteristic patches, plaques, and in later stages, tumours and erythroderma (generalised skin redness).
Chlormethine is a nitrogen mustard alkylating agent – one of the oldest classes of anticancer drugs. It works by binding to and cross-linking DNA strands in dividing cells, particularly at the N-7 position of guanine. This cross-linking creates structural damage to the DNA that prevents the malignant T-cells from replicating and transcribing genetic information, ultimately leading to cell death (apoptosis). Because the gel formulation delivers the drug directly to the skin surface, it acts locally on the cancerous cells with minimal systemic absorption, which significantly reduces the risk of the widespread side effects typically associated with intravenous chemotherapy.
The use of topical nitrogen mustard for CTCL has a long clinical history dating back several decades. Before Ledaga, chlormethine was compounded by pharmacies in various formulations (ointments, aqueous solutions), but these preparations were difficult to standardise and often caused variable skin reactions. Ledaga represents the first commercially manufactured, standardised gel formulation of chlormethine approved by the European Medicines Agency (EMA) and other regulatory authorities. This standardisation ensures consistent drug delivery, improved stability, and better clinical outcomes compared to compounded preparations.
Ledaga is indicated specifically for adults with CTCL of the MF type. It is used as a skin-directed therapy, which means it targets the disease where it manifests – in the skin – rather than through systemic drug delivery. Skin-directed therapies are a cornerstone of treatment for early-stage mycosis fungoides (stages IA–IIA), and Ledaga may also be used as part of a combined treatment approach in more advanced stages. Your oncologist or dermatologist will determine whether Ledaga is appropriate for your specific clinical situation, taking into account the stage of disease, extent of skin involvement, previous treatments, and overall health status.
Mycosis fungoides typically progresses slowly over years or even decades. Many patients with early-stage disease have an excellent long-term prognosis. Skin-directed therapies like Ledaga aim to control symptoms, improve skin appearance, and prevent disease progression while maintaining quality of life. The National Comprehensive Cancer Network (NCCN) and the European Organisation for Research and Treatment of Cancer (EORTC) both include topical chlormethine as a recommended first-line treatment option for early-stage MF.
What Should You Know Before Using Ledaga?
Before starting Ledaga, inform your doctor about any allergies (especially to chlormethine), any previous skin reactions, and whether you are pregnant or breastfeeding. The gel must never contact the eyes, nose, mouth, or mucous membranes, and caregivers must always wear nitrile gloves during application.
Contraindications
You should not use Ledaga if you are allergic (hypersensitive) to chlormethine or any of the other ingredients in the gel. Allergic reactions can manifest as sudden swelling of the lips, face, throat, or tongue, skin rash, or difficulty breathing. If you have ever experienced an allergic reaction to any formulation of chlormethine (mechlorethamine), including compounded preparations used in the past, you must inform your doctor before treatment is considered.
Warnings and Precautions
Talk to your doctor or pharmacist before using Ledaga. Several important safety precautions must be carefully observed throughout the entire course of treatment.
Eye exposure: Contact with the eyes must be strictly avoided at all times. Do not apply Ledaga near the eyes, on the inside of the nostrils, on the inside of the ears, or on the lips. If Ledaga accidentally gets into the eyes, it can cause pain, burning, swelling, redness, sensitivity to light, and blurred vision. In severe cases, it can lead to permanent eye damage or blindness. If eye exposure occurs, immediately flush the eyes with copious amounts of water, 0.9% sodium chloride solution, or an eye wash solution for at least 15 minutes, and seek emergency medical care including an ophthalmologist as soon as possible.
Mucosal exposure: If the gel comes into contact with the mouth or nose, it can cause pain, redness, and potentially severe ulceration. Immediately rinse the affected area with large amounts of water for at least 15 minutes and seek medical attention promptly.
Skin reactions: Ledaga commonly causes skin reactions at the application site, including dermatitis (inflammation with redness and swelling), itching, blistering, ulceration, and skin infections. The risk of skin inflammation is increased when Ledaga is applied to the face, genital area, anus, or skin folds. Your doctor will monitor your skin regularly and may temporarily or permanently discontinue treatment if reactions become severe.
Skin cancer risk: Cases of skin cancer (abnormal growth of skin cells) have been reported in patients using topical chlormethine, although a direct causal relationship has not been established. Your doctor will examine your skin for signs of skin cancer both during and after treatment with Ledaga. Report any new skin lesions, sores, or changes in existing skin areas to your doctor promptly.
Protection of others: Direct skin contact with Ledaga must be avoided by anyone other than the patient. Caregivers face the same risks of skin inflammation, eye damage, and mucosal injury. Caregivers who accidentally come into contact with Ledaga must wash the affected area immediately with soap and water for at least 15 minutes. Remove and launder any contaminated clothing. Seek immediate medical attention if the gel contacts the eyes, mouth, or nose.
Flammability: Ledaga contains isopropyl alcohol and is considered flammable. Do not expose treated skin to open flames or lit cigarettes until the gel has dried completely on the skin.
Children and Adolescents
Ledaga should not be given to children and adolescents under 18 years of age. The safety and efficacy of chlormethine gel have not been established in this age group. Mycosis fungoides is exceptionally rare in the paediatric population, and there is insufficient clinical data to support its use in patients younger than 18 years.
Pregnancy and Breastfeeding
If you are pregnant, think you may be pregnant, or are planning to become pregnant, consult your doctor before using Ledaga. There is limited experience with chlormethine in pregnant women. As an alkylating agent, chlormethine has the potential to cause harm to the developing foetus by damaging DNA in dividing cells. Therefore, Ledaga is not recommended during pregnancy or for women of childbearing potential who are not using effective contraception.
It is not known whether Ledaga is excreted in breast milk. Additionally, there is a risk that a breastfed infant could be exposed to the drug through direct skin contact with the mother's treated skin areas. For these reasons, breastfeeding is not recommended during treatment with Ledaga. Discuss the benefits of breastfeeding versus the benefits of Ledaga treatment with your doctor to make an informed decision.
Driving and Operating Machinery
Ledaga is not expected to have any effect on your ability to drive a car or operate machinery. The gel acts locally on the skin, and systemic absorption is minimal. No studies on the effect on driving or operating machinery have been performed, but based on the pharmacological profile of topical chlormethine, no impairment is anticipated.
Important Information About Ingredients
Ledaga contains propylene glycol, which may cause skin irritation in some individuals. It also contains butylhydroxytoluene (BHT), which may cause local skin reactions (such as contact dermatitis) or irritation to the eyes and mucous membranes. If you have known sensitivities to either of these excipients, inform your doctor before starting treatment.
How Does Ledaga Interact with Other Drugs?
No formal drug interaction studies have been conducted with Ledaga. Because chlormethine gel is applied topically with minimal systemic absorption, clinically significant drug interactions are not expected. However, you should avoid applying other topical products near treated skin areas within 2 hours of Ledaga application.
Inform your doctor or pharmacist about all medications you are currently taking, have recently taken, or might take, including prescription medicines, over-the-counter products, and herbal remedies. While systemic drug interactions are unlikely due to the topical route of administration and minimal systemic absorption, certain precautions regarding concurrent topical products should be observed.
Because Ledaga is applied directly to the skin and acts locally, the concentration of chlormethine in the bloodstream is negligible. This means that the typical drug-drug interactions seen with intravenously administered alkylating agents (such as interactions with other cytotoxic drugs, immunosuppressants, or drugs metabolised by hepatic enzymes) are not expected to occur with topical Ledaga. No formal pharmacokinetic interaction studies have been conducted.
Topical Product Interactions
| Product Type | Interaction Concern | Recommendation |
|---|---|---|
| Emollients and moisturisers | May alter Ledaga absorption or reduce contact with skin | Do not apply within 2 hours before or after Ledaga |
| Topical corticosteroids | May mask skin reactions that require treatment modification | Discuss timing and use with your doctor |
| Other topical medications | May interact locally or alter skin permeability | Do not apply within 2 hours before or after Ledaga |
| Sunscreens | May form a barrier affecting Ledaga absorption | Apply sunscreen at least 2 hours before or after Ledaga |
| Airtight/waterproof bandages | May increase local absorption and skin irritation | Do not cover treated areas with occlusive dressings |
The 2-hour window before and after Ledaga application is recommended to ensure that no other topical product interferes with the gel's contact with the skin or alters its absorption characteristics. If you are using multiple topical treatments for your skin condition, your dermatologist will provide a specific schedule to optimise the effectiveness of each product while minimising the risk of adverse reactions.
Although systemic drug interactions are not expected, patients receiving concurrent systemic chemotherapy, immunotherapy, or phototherapy (such as PUVA or narrowband UVB) for CTCL should discuss the combined treatment plan with their oncologist or dermatologist. The potential for additive skin toxicity should be considered when combining Ledaga with other skin-directed therapies.
What Is the Correct Dosage of Ledaga?
Apply a thin film of Ledaga gel to the affected skin areas once daily. The gel should be applied to completely dry skin at least 4 hours before or 30 minutes after bathing. Let it dry for 5–10 minutes before dressing. The same dose applies to all adult patients including the elderly.
Always use Ledaga exactly as your doctor or pharmacist has told you. If you are unsure, ask your doctor or pharmacist. Ledaga is for topical (skin) use only and must never be taken by mouth or applied to mucous membranes.
Adults (Including Elderly Patients)
Standard Dosage for All Adults
Dose: Apply a thin film once daily to affected skin areas
Frequency: Once daily
Timing: At least 4 hours before, or 30 minutes after, showering or washing
Drying time: Allow 5–10 minutes for the gel to dry before putting on clothes
The dose is the same for elderly patients (65 years and older) as for younger adults (18 years and older). No dose adjustment based on age is required.
Step-by-Step Application Instructions
Proper application of Ledaga is essential for both treatment effectiveness and safety. Follow these steps carefully every time you apply the gel:
- Caregiver preparation: If someone else is applying the gel to you, they must wear disposable nitrile gloves (a specific type of protective glove – ask your pharmacist if you have questions).
- Open the tube: Remove the cap just before use. Use the cap to puncture the seal on a new tube.
- Temperature timing: Apply the gel immediately or within 30 minutes of removing it from the refrigerator.
- Apply to dry skin: Ensure the skin is completely dry. Apply a thin layer to the affected skin areas only.
- Avoid unaffected areas: If the gel accidentally contacts unaffected (healthy) skin, wash those areas immediately with soap and water.
- Allow to dry: Let the treated areas dry for 5–10 minutes before putting on clothes.
- For patients applying the gel themselves: Wash your hands thoroughly with soap and water immediately after application.
- For caregivers: Remove the nitrile gloves carefully (turning them inside out during removal to avoid contact with Ledaga) and then wash hands thoroughly with soap and water.
- Store properly: With clean hands, return the tube to its original carton and place it inside the child-resistant, transparent, resealable plastic bag. Return it to the refrigerator immediately.
- Do not cover treated areas with airtight or waterproof bandages after application
- Avoid open flames or lit cigarettes until the gel has dried on the skin (the gel contains alcohol and is flammable)
- Do not apply emollients, moisturisers, or other topical products within 2 hours before or after Ledaga application
- Keep the gel away from children and food at all times
Children and Adolescents
Ledaga is not approved for use in patients under 18 years of age. The safety and efficacy of chlormethine gel have not been established in the paediatric population. If you are concerned about a skin condition in a child or adolescent, consult a paediatric dermatologist for appropriate evaluation and management.
Treatment Interruption and Dose Modification
Your doctor may temporarily stop Ledaga treatment if you develop severe skin inflammation (marked redness and swelling), blistering, or ulceration at the application sites. Treatment can typically be restarted once the skin reactions have improved to a manageable level. Your doctor will assess the severity of the reaction and determine the appropriate time to resume therapy. Do not restart treatment on your own without medical guidance.
Missed Dose
If you forget to apply Ledaga, do not apply a double dose to make up for the missed application. Simply apply the next dose at your usual scheduled time. If you frequently forget to apply the gel, consider setting a daily reminder or linking the application to a consistent daily routine. Consistent daily application is important for optimal treatment outcomes.
Overdose
Do not apply Ledaga more than once per day. Applying more gel than recommended may increase the severity of local skin reactions, including dermatitis, blistering, and ulceration. If you have applied significantly more gel than instructed, or if accidental ingestion occurs, contact your doctor or poison control centre immediately. Given the topical nature of the medication, systemic overdose is unlikely, but increased local toxicity can be clinically significant.
Stopping Ledaga
Your doctor will decide how long you need to use Ledaga based on your individual response to treatment, the extent and severity of your skin lesions, and any side effects experienced. Do not stop using Ledaga without consulting your doctor, even if your skin appears to be improving. Premature discontinuation may allow the disease to progress or relapse. If your doctor decides to stop Ledaga therapy, they may transition you to an alternative skin-directed treatment or systemic therapy depending on your clinical situation.
What Are the Side Effects of Ledaga?
The most common side effects of Ledaga occur at the application site and include dermatitis (skin inflammation), skin infections, and itching, affecting more than 1 in 10 patients. Less common side effects include skin ulcers, blistering, and skin darkening. Serious allergic reactions are possible and require immediate medical attention.
Like all medicines, Ledaga can cause side effects, although not everybody gets them. Because Ledaga is a topical medication with minimal systemic absorption, the vast majority of side effects are localised to the skin at or near the application sites. The severity of skin reactions often depends on the site of application (face, skin folds, and genital areas are more sensitive) and individual patient susceptibility.
- Swelling of the lips, face, throat, or tongue (signs of angioedema)
- Widespread skin rash or hives beyond the treatment area
- Difficulty breathing or wheezing
These may be signs of a serious allergic (hypersensitivity) reaction that requires emergency treatment.
Very Common
May affect more than 1 in 10 people
- Dermatitis (skin inflammation with redness and swelling at the application site)
- Skin infections at the treatment area
- Pruritus (itching at the application site)
Common
May affect up to 1 in 10 people
- Skin ulceration (open sores at the treatment area)
- Blistering of the skin at the application site
- Hyperpigmentation (darkening of the skin at treated areas)
Managing Skin Reactions
Skin reactions are an expected part of Ledaga therapy and do not necessarily mean the treatment needs to be permanently stopped. Many patients experience mild to moderate dermatitis during the initial weeks of treatment, which may improve with continued use. However, severe reactions warrant medical evaluation and possible treatment interruption.
Your doctor may recommend the following strategies to manage skin reactions:
- Mild dermatitis: Continue Ledaga application but monitor closely. Emollient use (observing the 2-hour separation) may help with dryness and discomfort.
- Moderate dermatitis or itching: Your doctor may prescribe a topical corticosteroid to apply to affected areas (at least 2 hours before or after Ledaga). Oral antihistamines may help with itching.
- Severe dermatitis, blistering, or ulceration: Treatment will typically be paused until symptoms improve significantly, after which Ledaga may be restarted at your doctor's discretion.
The risk of skin infections is increased because dermatitis can compromise the skin's natural barrier function. Signs of skin infection include increased redness, warmth, swelling, pain, crusting, or oozing at the application site. Report any signs of infection to your doctor promptly, as antibiotic treatment may be necessary.
Skin Cancer Monitoring
Skin cancer has been reported in patients who have received topical chlormethine, although it is not definitively known whether chlormethine directly causes these cancers. Patients with CTCL may already have an increased risk of developing secondary skin malignancies. Your dermatologist will perform regular skin examinations during and after Ledaga treatment to detect any new or suspicious skin lesions. Report any new moles, non-healing sores, or changes in existing skin lesions to your doctor immediately.
Reporting Side Effects
If you experience any side effects, including those not listed here, talk to your doctor or pharmacist. You can also report side effects directly to your national medicines regulatory authority. By reporting side effects, you help provide valuable information about the ongoing safety of this medicine.
How Should You Store Ledaga?
Ledaga must always be stored in the refrigerator at 2°C to 8°C (36°F to 46°F). Keep the tube in its original carton inside the child-resistant, resealable plastic bag. Discard both opened and unopened tubes after 60 days of refrigerated storage.
Proper storage of Ledaga is critical to maintaining the stability and effectiveness of the chlormethine gel. Because chlormethine is a chemically reactive alkylating agent, it can degrade if stored at incorrect temperatures, potentially reducing its therapeutic effect and altering its safety profile.
Storage Conditions
- Temperature: Always store at +2°C to +8°C (standard refrigerator temperature). Do not freeze.
- Protection: Keep the tube inside its original carton and within the child-resistant, transparent, resealable plastic bag provided.
- Shelf life after opening: Discard any opened or unopened tube after 60 days of storage in the refrigerator, regardless of how much gel remains.
- Expiry date: Do not use Ledaga after the expiry date printed on the tube label and carton. The expiry date refers to the last day of the stated month.
- Application timing: Apply the gel immediately or within 30 minutes of removing from the refrigerator. Return to the fridge immediately after use.
Safe Disposal
Ledaga is an anticancer medicine and must be disposed of carefully to protect others and the environment. Do not throw the tube, nitrile gloves, or plastic bags into household waste or flush them down the drain. Ask your pharmacist about local procedures for the safe disposal of cytotoxic medication waste. Some areas have designated collection programmes for hazardous pharmaceutical waste.
Keep Ledaga out of the sight and reach of children at all times. Store the tube in its protective packaging and plastic bag, and ensure the refrigerator is not accessible to young children without adult supervision.
What Does Ledaga Contain?
Each gram of Ledaga gel contains 160 micrograms of chlormethine as the active ingredient. The gel also contains several excipients including propylene glycol, isopropyl alcohol, glycerol, and menthol. Ledaga is a clear, colourless gel supplied in 60 g aluminium tubes.
Active Ingredient
The active substance is chlormethine (also known internationally as mechlorethamine). Each gram of gel contains 160 micrograms (0.016%) of chlormethine. Chlormethine is a bifunctional nitrogen mustard alkylating agent that exerts its anticancer effect by cross-linking DNA in malignant cells, thereby preventing cell division and promoting cell death.
Full List of Excipients
| Excipient | E Number | Function |
|---|---|---|
| Diethylene glycol monoethyl ether | – | Solvent / penetration enhancer |
| Propylene glycol | E 1520 | Solvent / humectant (may cause skin irritation) |
| Isopropyl alcohol | – | Solvent (flammable – gel must dry before exposure to flames) |
| Glycerol | E 422 | Humectant / moisturiser |
| Lactic acid | E 270 | pH adjustment |
| Hydroxypropylcellulose | E 463 | Thickening agent / gel former |
| Sodium chloride | – | Tonicity adjustment |
| Racemic menthol | – | Cooling / soothing agent |
| Disodium edetate | – | Chelating / stabilising agent |
| Butylhydroxytoluene (BHT) | E 321 | Antioxidant (may cause local skin reactions or eye irritation) |
Appearance and Packaging
Ledaga is a clear, colourless gel. Each aluminium tube contains 60 grams of gel and is fitted with a white screw cap. The tube is supplied inside a carton along with a child-resistant, transparent, resealable plastic bag for additional safety during storage. The marketing authorisation holder is Helsinn Birex Pharmaceuticals Ltd., based in Dublin, Ireland.
Frequently Asked Questions About Ledaga
Ledaga (chlormethine gel) is used to treat cutaneous T-cell lymphoma (CTCL) of the mycosis fungoides type in adults. Mycosis fungoides is a form of non-Hodgkin lymphoma where malignant T-lymphocytes accumulate in the skin, causing patches, plaques, and potentially tumours. Ledaga is applied as a thin film directly to the affected skin areas once daily, providing targeted therapy that acts locally against the cancerous cells while minimising systemic side effects.
Apply a thin film of Ledaga to the affected skin areas once daily. The skin must be completely dry – apply at least 4 hours before or 30 minutes after bathing. Allow the gel to dry for 5–10 minutes before putting on clothes. If someone else applies the gel for you, they must wear disposable nitrile gloves. Wash hands with soap and water immediately after application. Do not cover treated areas with airtight bandages. Return the tube to the refrigerator immediately after use.
If Ledaga accidentally gets into your eyes, immediately flush them with large amounts of water, 0.9% sodium chloride solution, or an eye wash solution for at least 15 minutes. Then seek emergency medical care, including an ophthalmologist (eye specialist), as soon as possible. Eye exposure to chlormethine can cause pain, burning, swelling, redness, sensitivity to light, blurred vision, and in severe cases, permanent eye damage or blindness. Prevention is critical – always wash your hands thoroughly after application and never touch your eyes while handling the gel.
Yes, you can use emollients and moisturisers during Ledaga treatment, but you must observe a separation period. Do not apply any emollients, creams, ointments, or other topical products (including sunscreen and other medications applied to the skin) within 2 hours before or 2 hours after applying Ledaga. This ensures that the gel has proper contact with the skin and that its absorption is not affected by other products. Your dermatologist can recommend suitable moisturisers and help you schedule their use around Ledaga application.
The duration of Ledaga treatment varies between patients and is determined by your doctor based on your individual response, disease stage, extent of skin involvement, and tolerability. Treatment may continue for months or even longer in some cases. Do not stop using Ledaga without consulting your doctor, even if your skin appears to improve, as premature discontinuation may lead to disease progression or relapse. Your dermatologist or oncologist will regularly assess your response and adjust the treatment plan accordingly.
Ledaga is not recommended during pregnancy or breastfeeding. Chlormethine is an alkylating agent that can damage DNA in dividing cells, and there is limited data on its safety in pregnant women. Women of childbearing potential should use effective contraception during treatment. Breastfeeding is also not recommended because it is unknown whether the drug passes into breast milk, and the nursing infant could be exposed to Ledaga through direct skin contact with the mother's treated areas. Discuss your options with your doctor if you are pregnant or planning a pregnancy.
References
- European Medicines Agency (EMA). Ledaga – Summary of Product Characteristics (SmPC). European Medicines Agency. Available at: ema.europa.eu/en/medicines/human/EPAR/ledaga.
- Lessin SR, Duvic M, Guitart J, et al. Topical chemotherapy in cutaneous T-cell lymphoma: positive results of a randomized, controlled, multicenter trial. Journal of the American Academy of Dermatology. 2013;69(6):953–961. doi:10.1016/j.jaad.2013.08.026
- National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology: Primary Cutaneous Lymphomas (Version 1.2026). NCCN Guidelines. Available at: nccn.org.
- Willemze R, Cerroni L, Kempf W, et al. The 2018 update of the WHO–EORTC classification for primary cutaneous lymphomas. Blood. 2019;133(16):1703–1714. doi:10.1182/blood-2018-11-881268
- Trautinger F, Eder J, Assaf C, et al. European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome – Update 2023. European Journal of Cancer. 2023;195:113343. doi:10.1016/j.ejca.2023.113343
- Kim YH, Liu HL, Mraz-Gernhard S, Varghese A, Hoppe RT. Long-term outcome of 525 patients with mycosis fungoides and Sézary syndrome. Archives of Dermatology. 2003;139(7):857–866. doi:10.1001/archderm.139.7.857
- World Health Organization (WHO). Model List of Essential Medicines – 23rd List (2023). Geneva: World Health Organization; 2023.
- British National Formulary (BNF). Mechlorethamine – Indications, dose, side effects. Available at: bnf.nice.org.uk.
Medical Editorial Team
This article was prepared and reviewed by iMedic's medical editorial team, comprising licensed specialist physicians with expertise in oncology, dermatology, and clinical pharmacology.
Content Preparation
iMedic Medical Writing Team
Specialist physicians in oncology and dermatology with expertise in cutaneous lymphoma management and pharmacological therapeutics.
Medical Review
iMedic Medical Review Board
Independent panel of board-certified physicians who review all content according to WHO, ESMO, and NCCN guidelines using the GRADE evidence framework.
Editorial Standards: All medical content on iMedic follows evidence level 1A standards based on systematic reviews and meta-analyses of randomised controlled trials. Content is regularly reviewed and updated to reflect the latest clinical evidence and guideline recommendations. iMedic receives no pharmaceutical industry funding and maintains complete editorial independence. Read our full editorial policy.